DNA Mapping At Birth is the Norm to Avoid Disease Risk
The evolution of micro-total analysis systems (singlecell analysis) and advancements in nanotechnology, coupled with more widespread Big Data technologies, make DNA-mapping at birth the norm, as well as part of one’s annual physician exam.
For a look ahead, Thomson Reuters analysts consulted the Web of Science and Derwent World Patents Index to identify rapid progress and emergent trends in scientific research and technological innovation, gauging the advances most likely to affect health and the quality of life in the next decade.
With the proliferation of individual gene mapping, and Big Data yielding an increasing store of information on gene expression and variation and their role in disease, the medical processes of screening and prevention will be transformed.
As the volume of matter which can be manipulated in the lab gets smaller and smaller, greater possibilities for precise medical screening emerge. Blood tests potentially become a thing of the past, as nano-probes will be inserted into a patient to gather data over longer periods of time and provide greater accuracy.
Micro-total analysis systems will be much closer to providing the sensitivity and selectivity required to make in vivo measurements for diagnosis. Single-cell analysis, currently in the research phase, will be mainstream and set to replace traditional flow cytometry for the isolation, purification and separation of cells in immunology testing.
Big Data will be embedded in society in the next decade, allowing medical researchers and physicians to use it to their advantage. In 2025, humans will have their DNA mapped at birth and checked annually to identify any changes that could point to the onset of autoimmune diseases.
Emerging research front – genomics, centered around two September 2012 research papers with over 1,000 citations: "An integrated encyclopaedia of DNA elements in the human genome” (800+ citations), and “The accessible chromatin landscape of the human genome" (200 citations)
January 2014 paper: "Genomescale CRISPR-CAS9 knockout screening in human cells" 4 citations
Note to Editors and Writers: For images and other resources, please visit our Editorial Resources page.
The data and citation records included in this report are from Thomson Reuters Web of ScienceTM. Web of ScienceTM is a registered trademark of Thomson Reuters. All rights reserved.